Related Experiment Video
Updated: Apr 29, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Biomarkers and personalized therapy in chronic kidney diseases
1University of Bari and CARSO Consortium , Policlinico, Piazza G. Cesare 11, 70124 Bari , Italy +39 080 5478869 ; +39 080 5575710 ; paolo.schena@uniba.it.
Abstract:
Numerous clinical trials are currently evaluating new strategies to halt the progression of renal damage in patients with chronic kidney diseases (CKDs). Unfortunately, none of them have considered that the lack of response to new therapies may be due to the pharmacogenetics/pharmacogenomics profile of the patient. The recent impact of high-throughput technologies used in genomics, proteomics and metabolomics may open a new way for discovering biomarkers that can provide us information about the mechanisms on the progression of renal damage. However, they can also be used for diagnosis and for selecting drugs, leading to personalized tailored therapy. The uses of classifiers formed by a list of genes, proteins and metabolites have been introduced into oncology and organ transplantation. These new approaches have recently also been used in the care of human glomerulonephritis. Integrating the large omic data sets with drug and disease databases could give the prediction of drug efficacy and side effects in CKDs.
Insights
New strategies for chronic kidney diseases (CKDs) may fail due to patient pharmacogenetics. Integrating omics data with databases can predict drug efficacy and side effects for personalized CKD therapy.
Area of Science:
- Nephrology
- Genomics
- Pharmacogenomics
Background:
- Current chronic kidney disease (CKD) trials often overlook patient-specific pharmacogenetic profiles, potentially explaining therapy non-response.
- High-throughput omics technologies (genomics, proteomics, metabolomics) offer novel biomarker discovery for renal damage mechanisms.
Discussion:
- Omics data integration with drug and disease databases can predict treatment efficacy and adverse events in CKD patients.
- Classifiers utilizing gene, protein, and metabolite lists, successful in oncology and transplantation, are now applicable to glomerulonephritis care.
Key Insights:
- Pharmacogenomics is a critical, yet often neglected, factor in CKD treatment outcomes.
- Personalized medicine approaches using omics data can optimize drug selection and improve patient care in CKD.
Outlook:
- Future CKD research should incorporate pharmacogenomic profiling for enhanced therapeutic strategies.
- Integrating multi-omics data holds significant promise for advancing personalized nephrology and improving patient management.
More Related Videos
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Acute Kidney Injury IV: Diagnostic Studies and Prevention

